Matwings Supports GenSci148 Protein Program Cleared for China Clinical Trial

Matwings said in a press release that GenSci148 Injection has received clinical trial clearance in China for neovascular age related macular degeneration, diabetic macular edema, and retinal vein occlusion. The investigational ophthalmic biologic was developed by GenSci, with Matwings supporting protein engineering work.

The program used four iterative AI and wet lab cycles covering 222 protein variants. The first two rounds tested 92 and 30 variants with a focus on biological activity, while the next two rounds tested 50 variants each and added objectives such as formulation viscosity, stability, expression, and broader developability.

Tested variants showed up to about 10 fold improvement in VEGF A binding affinity, up to about 3 fold improvement in VEGF A, C, and D functional blockade, thermal stability gains of up to about 4.5°C, protein expression gains of up to about 27.6%, and viscosity reduction of about 13 cP in high concentration formulation. In a nonclinical retinal model, the optimized molecule maintained inhibitory activity 84 days after dosing. The findings are preclinical and do not establish clinical safety or efficacy.